Evidence map›Paper›PMID 26763971›Full record

ArticleJournal of clinical microbiology2016

MTBDRplus and MTBDRsl Assays: Absence of Wild-Type Probe Hybridization and Implications for Detection of Drug-Resistant Tuberculosis.

Marva Seifert, Sophia B Georghiou, Donald Catanzaro, Camilla Rodrigues, Valeriu Crudu, Thomas C Victor, Richard S Garfein, Antonino Catanzaro, Timothy C Rodwell

Open access · bronzeAbstract readComparative StudyEvaluation Study
In one paragraph

Article in Journal of clinical microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Observational
  13. Article
  14. Article
  15. Some Synonymous and NonsynonymousAntimicrobial agents and chemotherapy · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 4 countries.

Marva SeifertUniversity of California, San Diego, California, USA mseifert@ucsd.edu.
Sophia B GeorghiouUniversity of California, San Diego, California, USA.
Donald CatanzaroUniversity of Arkansas, Fayetteville, Arkansas, USA.
Camilla RodriguesHinduja National Hospital, Mumbai, India.
Valeriu CruduInstitute of Phthisiopneumology, Chisinau, Moldova.
Thomas C VictorStellenbosch University, Cape Town, South Africa.
Richard S GarfeinUniversity of California, San Diego, California, USA.
Antonino CatanzaroUniversity of California, San Diego, California, USA.
Timothy C RodwellUniversity of California, San Diego, California, USA.
University of California, San Diego · USP. D. Hinduja Hospital and Medical Research Centre · INPhthisiopneumology Institute "Chiril Draganiuc" · MDStellenbosch University · ZAUniversity of Arkansas at Fayetteville · US

Funding

VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Maile Ann Young Karris · 1994 to 2026
$78.4M
Rapid Tests for Drug Resistance to Detect Extensively Drug-Resistant TuberculosisU01AI082229 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CATANZARO, ANTONINO · 2009 to 2013
$10.9M
Training in the Next Generation in Respiratory ScienceT32HL134632 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MALHOTRA, ATUL, POWELL, FRANK L. · 2017 to 2021
$2.1M
Training in Respiratory Biology: Innovate, Integrate, and TranslateT32HL098062 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI POWELL, FRANK L. · 2010 to 2014
$2.1M
NHLBI NIH HHS T32 HL098062NHLBI NIH HHS T32 HL134632NIAID NIH HHS 1U01AI082229-01NIAID NIH HHS P30 AI036214-20
6 · The paper itself

Abstract

Accurate identification of drug-resistantMycobacterium tuberculosisis imperative for effective treatment and subsequent reduction in disease transmission. Line probe assays rapidly detect mutations associated with resistance and wild-type sequences associated with susceptibility. Examination of molecular-level performance is necessary for improved assay result interpretation and for continued diagnostic development. Using data collected from a large, multisite diagnostic study, probe hybridization results from line probe assays, MTBDRplusand MTBDRsl, were compared to those of sequencing, and the diagnostic performance of each individual mutation and wild-type probe was assessed. Line probe assay results classified as resistant due to the absence of wild-type probe hybridization were compared to those of sequencing to determine if novel mutations were inhibiting wild-type probe hybridization. The contribution of absent wild-type probe hybridization to the detection of drug resistance was assessed via comparison to a phenotypic reference standard. In our study, mutation probes demonstrated significantly higher specificities than wild-type probes and wild-type probes demonstrated marginally higher sensitivities than mutation probes, an ideal combination for detecting the presence of resistance conferring mutations while yielding the fewest number of false-positive results. The absence of wild-type probe hybridization without mutation probe hybridization was determined to be primarily the result of failure of mutation probe hybridization and not the result of novel or rare mutations. Compared to phenotypic culture-based drug susceptibility testing, the absence of wild-type probe hybridization without mutation probe hybridization significantly contributed to the detection of phenotypic rifampin and fluoroquinolone resistance with negligible increases in false-positive results.

Indexed as

Antitubercular AgentsHumansMicrobial Sensitivity TestsMolecular Diagnostic TechniquesMutationMycobacterium tuberculosisNucleic Acid HybridizationProspective StudiesSensitivity and SpecificitySequence Analysis, DNATuberculosis, Multidrug-ResistantAntitubercular Agents

Identifiers

PMID26763971
PMCPMC4809938
OpenAlexW2233411062

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.